Addition of Rituximab to a CEOP Regimen Improved the Outcome in the Treatment of Non-Germinal Center Immunophenotype Diffuse Large B Cell Lymphoma Cells with High Bcl-2 Expression.
International Journal of Hematology（2013）
Key words
Diffuse large B cell lymphoma,Immunophenotyping,Bcl-2,Prognosis,Rituximab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined